Question to the Department of Health and Social Care:

To ask His Majesty's Government what progress has been made regarding talks taking place between AstraZeneca, Daiichi Sankyo, NHS England and NICE about the HER2-low metastatic breast cancer treatment Enhertu.

I am pleased to confirm that, on 17 September, the National Institute for Health and Care Excellence (NICE) announced that it is recommending Enhertu for use on the National Health Service for the treatment of certain types of breast cancer.

This is the result of an improved pricing arrangement from the companies, together with the impact of (a) recent changes to NICE's cost-effectiveness thresholds, arising from the UK-US Pharmaceutical Partnership announced on 2 April, and (b) new methods adopted by NICE for assessing quality of life, published on 27 August. Taken together, these changes mean the treatment can now be recommended for routine NHS use.